Diplacone
Based on 1 Customer Validation
Diplacone is an orally active geranyl flavanone. It is isolated from the fruits of Paulownia tomentosa. Diplacone reduces COX-2 levels and increases the pro-MMP2/MMP2 ratio. It induces ferroptosis-mediated cell death. Diplacone enhances mitochondrial Ca2+ influx and ROS production. It possesses anti-inflammatory and free radical-scavenging activities. Diplacone can be used in research related to ulcerative colitis and non-small cell lung cancer.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 98.38%
- CAS. Nr.: 73676-38-7
- Formel: C25H28O6
- Molecular Weight:424.49
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Alle Calcium Channel Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
IC50 & Target
[1]|
COX-2 |
MMP-2 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A2780 | IC50 |
5.5 μg/mL
Compound: 4
|
Cytotoxicity against human A2780 cells
Cytotoxicity against human A2780 cells
|
[PMID: 15787448] |
| A2780cisR | IC50 |
10.5 μM
Compound: 10
|
Antiproliferative activity against drug-sensitive human A2780 cells
Antiproliferative activity against drug-sensitive human A2780 cells
|
[PMID: 17326683] |
| A549 | IC50 |
4 μM
Compound: Nymphaeol A
|
Growth inhibition of human A549 cells
Growth inhibition of human A549 cells
|
[PMID: 28814374] |
| BC | IC50 |
2.7 μg/mL
Compound: 4
|
Cytotoxicity against human BC cells
Cytotoxicity against human BC cells
|
[PMID: 15974621] |
| BJ | EC50 |
5.9 μM
Compound: 8
|
Cytotoxicity against human BJ cells assessed as viable cells after 72 hrs by calcein AM assay
Cytotoxicity against human BJ cells assessed as viable cells after 72 hrs by calcein AM assay
|
[PMID: 20192247] |
| CCRF-CEM | EC50 |
3.2 μM
Compound: 8
|
Cytotoxicity against human CEM cells assessed as viable cells after 72 hrs by calcein AM assay
Cytotoxicity against human CEM cells assessed as viable cells after 72 hrs by calcein AM assay
|
[PMID: 20192247] |
| HeLa | EC50 |
<10 μM
Compound: 8
|
Cytotoxicity against human HeLa cells assessed as viable cells after 72 hrs by calcein AM assay
Cytotoxicity against human HeLa cells assessed as viable cells after 72 hrs by calcein AM assay
|
[PMID: 20192247] |
| KB | IC50 |
4.6 μg/mL
Compound: 4
|
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
|
[PMID: 15974621] |
| MCF7 | EC50 |
<10 μM
Compound: 8
|
Cytotoxicity against human MCF7 cells assessed as viable cells after 72 hrs by calcein AM assay
Cytotoxicity against human MCF7 cells assessed as viable cells after 72 hrs by calcein AM assay
|
[PMID: 20192247] |
| NCI-H187 | IC50 |
1.5 μg/mL
Compound: 4
|
Cytotoxicity against human NCI-H187 cells
Cytotoxicity against human NCI-H187 cells
|
[PMID: 15974621] |
| RPMI-8226 | EC50 |
<10 μM
Compound: 8
|
Cytotoxicity against human RPMI8226 cells assessed as viable cells after 72 hrs by calcein AM assay
Cytotoxicity against human RPMI8226 cells assessed as viable cells after 72 hrs by calcein AM assay
|
[PMID: 20192247] |
| THP-1 | EC50 |
<10 μM
Compound: 8
|
Cytotoxicity against human THP1 cells after 72 hrs by erythosin B staining method
Cytotoxicity against human THP1 cells after 72 hrs by erythosin B staining method
|
[PMID: 20192247] |
| THP-1 | IC50 |
>10 μM
Compound: 22
|
Cytotoxicity against human THP1 cells assessed as cell viability after 24 hrs by WST assay
Cytotoxicity against human THP1 cells assessed as cell viability after 24 hrs by WST assay
|
[PMID: 25735399] |
| U-266 | EC50 |
2.4 μM
Compound: 8
|
Cytotoxicity against human U266 cells assessed as viable cells after 72 hrs by calcein AM assay
Cytotoxicity against human U266 cells assessed as viable cells after 72 hrs by calcein AM assay
|
[PMID: 20192247] |
| Vero | IC50 |
3.8 μg/mL
Compound: 4
|
Cytotoxicity against african green monkey Vero cells
Cytotoxicity against african green monkey Vero cells
|
[PMID: 15974621] |
In Vitro
Diplacone inhibits LPS-induced inflammatory responses and reduces the expression of COX-2 in mouse macrophages[1].
Diplacone (pre-incubated for 1 h before lipopolysaccharide stimulation at concentrations of 10-20 μM) downregulates the gene expression of LPS-induced pro-inflammatory factors TNF-α and MCP-1, and upregulates the expression of LPS-induced anti-inflammatory gene ZFP36. In macrophages differentiated from the THP-1 human monocytic leukemia cell line, it doubles the total production of TNF-α mRNA, halves the total production of MCP-1 mRNA, and slightly increases the total production of ZFP36 mRNA[2].
Diplacone (5-40 μM; 24-48 h) potently inhibits the viability of human non-small cell lung cancer A549 cells, with an IC50 value of 10.6 μM at 24 h and 7.9 μM at 48 h[3].
Diplacone (20-40 μM; 1 min) increases the cytoplasmic Ca2+ concentration in non-small cell lung cancer A549 cells[3].
Diplacone (20-40 μM; 3-24 h) induces loss of mitochondrial membrane potential in non-small cell lung cancer A549 cells[3].
Diplacone (40 μM; 3-24 h) induces time-dependent upregulation of ATF3 protein expression in non-small cell lung cancer A549 cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Differentiated THP-1 human monocytic leukaemia cell line-derived macrophages
-
Concentration:10 μM; 20 μM
-
Incubation Time:1 h (pre-incubation); 1, 2, 4, 6, 10, 24 h (post-LPS stimulation harvest)
-
Result:Significantly decreased TNF-α gene expression at 2 h post-LPS (P < 0.001) and significantly increased it at 4, 10, and 24 h post-LPS (P < 0.05) at 10 μM.
Significantly decreased TNF-α gene expression at 2 h post-LPS (P < 0.001), significantly decreased it at 1 h post-LPS (P < 0.05), and significantly increased it at 24 h post-LPS (P < 0.05) at 20 μM.
Significantly decreased MCP-1 gene expression at 4 h post-LPS (P < 0.0005), 6 h post-LPS (P < 0.0001), and 10 h post-LPS (P < 0.0001) at 10 μM.
Significantly decreased MCP-1 gene expression at 4 h post-LPS (P < 0.0001), 6 h post-LPS (P < 0.0001), and 10 h post-LPS (P < 0.0001) at 20 μM.
-
Cell Line:A549 human non-small cell lung cancer cells
-
Concentration:5-40 μM
-
Incubation Time:24 h; 48 h
-
Result:Inhibited A549 cell viability in a dose-dependent manner.
Reached IC50 values of 10.6 μM (24 h) and 7.9 μM (48 h).
-
Cell Line:A549 human non-small cell lung cancer cells
-
Concentration:40 μM
-
Incubation Time:3, 6, 9, 12, 24 h
-
Result:Increased ATF3 protein expression in a time-dependent manner, with relative expression levels of 2.75-fold (3 h), 3.58-fold (6 h), 2.87-fold (9 h), 2.9-fold (12 h), and 3.2-fold (24 h) compared to control.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wistar rats (male, 180-220 g, ulcerative colitis induced by 10% DSS in drinking water for 5 days)[1]
-
Dosage:25 mg/kg
-
Administration:i.g.; 48 h and 24 h pre-colitis induction, then every 24 h during DSS exposure
-
Result:Ameliorated colitis symptoms (diarrhea, rectal bleeding) and delayed symptom onset.
Showed the lowest disease activity index (DAI) on the final day of the experiment, with a statistically significant reduction compared to the DSS-only group (### p < 0.001).
Reduced colon weight/length ratio increase to 20.4% relative to the intact group.
Reduced colonic COX-2 levels by 55.9% compared to the DSS-only group.
Increased the pro-MMP2/MMP2 ratio by 50.7% compared to the DSS-only group.
Reduced colonic levels of antioxidant enzymes SOD2 and CAT.
Resulted in an 87.5% survival rate (1 of 8 rats died).
Chemical Information
-
CAS. Nr. 73676-38-7
-
Appearance Solid
-
Molecular Weight 424.49
-
Formel C25H28O6
-
Color White to off-white
-
SMILES
OC1=C2C(O[C@H](C3=CC(O)=C(C=C3)O)CC2=O)=CC(O)=C1C/C=C(C)/CC/C=C(C)\C
-
Synonyms
Nymphaeol A; Propolin C
-
Structure Classification
-
Initial Source
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Protokoll
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
DSS-Induced Colitis
Dextran sulfate sodium (DSS)-induced colitis is generated by administering DSS in mouse drinking water, producing epithelial injury, barrier disruption, weight loss, diarrhea, fecal blood, colon shortening, histologic mucosal damage, and inflammatory mediator changes; the model is mainly used to study acute or chronic intestinal inflammation resembling selected features of ulcerative colitis. DSS injury is interpreted through clinical and tissue readouts rather than a single molecular endpoint: daily body weight, stool consistency, and bleeding are combined into a disease activity index, while colon length, histology, cytokines, myeloperoxidase activity, intestinal permeability, and tight-junction markers provide complementary measures of inflammation and barrier damage.
-
TNBS-Induced Colitis
TNBS-induced colitis is produced by intrarectal delivery of 2,4,6-trinitrobenzene sulfonic acid in ethanol, where ethanol disrupts the mucosal barrier and TNBS haptenates colonic proteins, generating immune-mediated colonic inflammation with weight loss, diarrhea, ulceration, transmural injury, inflammatory-cell infiltration, and cytokine responses. The model is used as an experimental intestinal inflammation model with Crohn’s disease–like features, especially when Th1-type responses, IL-12–dependent inflammation, chronic relapsing inflammation, or fibrosis-related endpoints are studied.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
-
Ca2+ Staining Technique
Ca2+ staining is an experimental technique that utilizes specific fluorescent probes (such as Fluo-4 AM, Fura-2, etc.) to qualitatively or quantitatively detect dynamic changes in intracellular Ca2+ concentrations; this is achieved by monitoring the changes in fluorescent signals generated when these probes bind to free intracellular calcium ions. The underlying principle relies primarily on the presence of chelating groups within the probe's molecular structure that possess high affinity for calcium ions.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Reinheit & Dokumentation
-
Data Sheet (276 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Vochyánová Z, et al. Diplacone and mimulone ameliorate dextran sulfate sodium-induced colitis in rats. Fitoterapia. 2015;101:201-207. [Content Brief]
[2]. Hosek J, et al. Effect of diplacone on LPS-induced inflammatory gene expression in macrophages. Folia Biol (Praha). 2010;56(3):124-130. [Content Brief]
[3]. Kang MJ, et al. Diplacone Isolated from Paulownia tomentosa Mature Fruit Induces Ferroptosis-Mediated Cell Death through Mitochondrial Ca2+ Influx and Mitochondrial Permeability Transition. Int J Mol Sci. 2023 Apr 11;24(8):7057. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)